Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Environ Int. 2020 Feb 20;137:105573. doi: 10.1016/j.envint.2020.105573

Table 3.

Prospective hazard ratio (HR) of hypertension relative to baseline plasma PFAS concentration (per doubling increase) among participants without hypertension at baseline

Cross-sectional Risk (N=957) Prospective Hazard (N=660)
Log-2 PFAS analytes RR (95% CI) HR (95% CI) Effect modification by treatment arm (p-value)b
. PFOS 1.06 (0.96, 1.17) 0.95 (0.84, 1.06) 0.25
. PFOA 1.08 (0.96, 1.21) 0.95 (0.83, 1.08) 0.33
. PFHxS 1.04 (0.96, 1.13) 0.94 (0.86, 1.03) 0.91
. EtFOSAA 0.98 (0.92, 1.04) 0.98 (0.92, 1.06) 0.12
. MeFOSAA 1.09 (1.01, 1.19) 0.95 (0.87, 1.03) 0.93
. PFNA 1.04 (0.95, 1.14) 0.99 (0.91, 1.08) 0.52

Note:

a

Hypertension defined as self-reported hypertension diagnosis, use of antihypertensive medication, systolic/diastolic blood pressure ≥140/90 mmHg or ≥130/80 mmHg for those with diabetes; All models adjusted for age, sex, race, treatment assignment, education, income, marital status, alcohol drinking, smoking, and DASH diet score.

b

Effect modification of baseline PFAS concentration by treatment arm assessed by adding a multiplicative term between plasma PFAS concentration and treatment assignment in the Cox-Proportional Hazard model.